Alumis Inc. Files 2024 10-K: $86M Assets, $2.7M Liabilities
Ticker: ALMS · Form: 10-K · Filed: Mar 19, 2025 · CIK: 1847367
| Field | Detail |
|---|---|
| Company | Alumis Inc. (ALMS) |
| Form Type | 10-K |
| Filed Date | Mar 19, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
Alumis 2024 10-K: $86M assets, $2.7M liabilities. Pharma biz.
AI Summary
Alumis Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting total assets of $85.96 million and total liabilities of $2.68 million. The company, formerly Esker Therapeutics, Inc., is involved in pharmaceutical preparations. Its principal executive offices are located at 280 East Grand Avenue, South San Francisco, CA.
Why It Matters
This filing provides a snapshot of Alumis Inc.'s financial health and operational status as of the end of 2024, which is crucial for investors and stakeholders to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — The filing is a standard annual report and does not contain immediate red flags or significant negative developments.
Key Numbers
- $85.96B — Total Assets (As of December 31, 2024)
- $2.68M — Total Liabilities (As of December 31, 2024)
- 2024-12-31 — Fiscal Year End (Reporting Period)
Key Players & Entities
- ALUMIS INC. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 280 EAST GRAND AVENUE (address) — Business Address
- SOUTH SAN FRANCISCO (location) — Business City
- CA (location) — Business State
- ESKER THERAPEUTICS, INC. (company) — Former Company Name
- 20230427 (date) — Date of Name Change
- 85960088 (dollar_amount) — Total Assets
- 2675979 (dollar_amount) — Total Liabilities
FAQ
What was Alumis Inc.'s net income or loss for the fiscal year ending December 31, 2024?
The provided excerpt does not explicitly state the net income or loss for the fiscal year ending December 31, 2024. It focuses on asset and liability figures.
What is the primary business of Alumis Inc.?
Alumis Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
When did Alumis Inc. change its name from Esker Therapeutics, Inc.?
The company changed its name from Esker Therapeutics, Inc. on April 27, 2023.
What are the principal executive offices of Alumis Inc.?
The principal executive offices of Alumis Inc. are located at 280 East Grand Avenue, South San Francisco, CA 94080.
What was the previous name of Alumis Inc. before Esker Therapeutics, Inc.?
Before being known as Esker Therapeutics, Inc., the company was named FL2021-001, Inc., with a name change date of February 22, 2021.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 19, 2025 regarding ALUMIS INC. (ALMS).